Johnson & Johnson invests US$780 million in new flu treatment drugs

Compileriver

When Johnson & Johnson launched the first products of its new crown vaccine in the United States, it was already focusing on the next pandemic.

A few days ago, Johnson & Johnson subsidiary Janssen will invest US$27 million to purchase Cidara’s leading antiviral conjugate CD388, which can treat and prevent all influenza strains with a single dose.

The current flu vaccine has several major limitations.

Cidara is responsible for R&D and production to the second phase.

Jeffrey Stein said in a conference call with investors on Monday morning that there is still a $753 million R&D budget and milestones waiting for Cidara, as well as "medium to high digit" tiered royalties.

The Janssen agreement also includes Cidara's another AVC candidate project CD377, which has a slightly shorter duration.

In addition to the agreement between Cidara and Mundipharma on its main antifungal project Rezafungin in 2019, the biotech company will receive up to US$1.

Reference source: With one pandemic still raging, J&J bets $780M on a potential flu therapy for the next